We are excited to announce Serbia's commencement of constructing the BIO4 campus in Belgrade! This campus is set to become a central hub for innovation, research and collaboration, uniting brilliant minds with cutting-edge technologies.
As Zdravlje, we are honoured to play a role in this ground-breaking project, poised to redefine the biotechnology landscape in Europe. Our commitment is to pioneer the development of novel biologics for the prevention and treatment of life-threatening diseases.
The successful and long-term business of Zdravlje was also recognized by the Chamber of Commerce of Serbia (PKS). At the premises of the Regional Chamber of Commerce (RPK) in Leskovac, during the ceremonial session of the Parliament of Businessmen, Zdravlje was presented with the JUBILEE AWARD OF THE CHAMBER OF COMMERCE OF SERBIA for 70 years of successful business.
Zdravlje Leskovac ceremoniously marked a significant milestone - seven decades of dedication to innovation, trust, and quality. The celebration, held on Friday, November 24, brought together more than 350 guests, including our business partners, collaborators, and representatives of institutions who, along with our employees, reminisced about the extensive history of Zdravlje.
Zdravlje/Frontier Biopharma has received another Marketing Authorisation in the CEE issued by the Bulgarian Drug Agency for PazoFront® 200mg and 400mg, film-coated tablets (INN: pazopanib). PazoFront’s active substance (pazopanib) is a protein kinase inhibitor that works by preventing the activity of proteins involved in the growth and spread of cancer cells.
To mark this week’s second Biotech Future Forum in Belgrade, our CEO, Kiren L. Naidoo, reaffirms Zdravlje’s commitment to building the biotechnology industry in Serbia. Through valuable partnerships with the Government of the Republic of Serbia, academia, and leading international partners, Frontier Biopharma and Zdravlje are set to lead the biotechnology industry in the region across critical areas such as next-generation vaccines, cell & gene therapies – all domestically produced and intended to serve patients locally and abroad.
[Belgrade, Serbia, 8 September 2023] Frontier Biopharma Limited today announced the signing of a Memorandum of Understanding (“MoU”) between the Government of Serbia, SK Bioscience and Frontier Biopharma to establish a vaccines development and manufacturing hub in Serbia.
Zdravlje is pleased to announce that as of 16 August 2023, Dragana Grujic Stosic has joined Zdravlje’s Commercial team as a Marketing Manager. She will be responsible for leading our product managers team and building our strategic marketing expertise to ensure the targeted growth. Dragana will report directly to Dmitriy Sovetkin, Commercial Director.
On the occasion of the “World Environment Day” – June 5 – focusing this year on the theme: #BeatPlasticPollution, we are proud to join the global campaign as a socially and environmentally responsible company and as Zdravlje employees highly aware of the importance of our individual and collective contribution to the outcome of this continuous battle.
Zdravlje AD is delighted to announce the appointment of Dr. Dmitriy Sovetkin to its leadership team as Commercial Director, effective June 1, 2023. Dr. Sovetkin will report to Group CEO, Kiren Naidoo.
Dmitriy brings over 20 years of proven success as an experienced leader within the pharmaceutical industry. He has deep expertise across various functions including sales and marketing, business development, regulatory affairs, finance and manufacturing, amongst others.
Frontier Pharma Limited and Zdravlje AD are pleased to announce that Mr. Vishal Kumar Gupta has joined our leadership team as Group Chief Financial Officer, reporting to Kiren Naidoo (CEO).
Vishal joins us from the United Kingdom and brings c. 15 years’ experience in various leadership positions including at Essar Oil UK, the owners of Stanlow Refinery with c. $10 billion in annual revenue.